Glargine-treated patients do not show higher cancer risk

07/29/2013 | MedPage Today (free registration)

A study in Diabetes Care showed patients who began treatment with insulin glargine had a nonsignificant 12% higher cancer incidence at one year compared with those on human neutral protamine Hagedorn insulin. Researchers also found women on glargine therapy for more than two years did not have a higher risk of breast cancer than those on NPH, while glargine-treated men had a nonsignificant 2.66-fold increased risk of prostate cancer at 12 to 24 months compared with the NPH group.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA